Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP3 | Q9NSD7 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5843753 | 0.86 | RXFP3 (0.56) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5842780 | 0.86 | SMN1; SMN2 (0.57) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5842936 | 0.85 | RXFP3 (0.53) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5843197 | 0.84 | RXFP3 (0.52) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5841684 | 0.84 | ALDH1A1 (0.44) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5842943 | 0.84 | RXFP3 (0.51) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5843797 | 0.82 | NPC1 (0.48) | RXFP3MAPTALDH1A1PKMKMT2A | |
| SCHEMBL5843190 | 0.82 | RXFP3 (0.50) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5841945 | 0.82 | CYP2D6 (0.44) | RXFP3SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL5843929 | 0.81 | ALDH1A1 (0.64) | RXFP3SMN1; SMN2MAPTALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | RXFP3 52/4885SMN1; SMN2 3678/4885MAPT 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.